132 related articles for article (PubMed ID: 37573161)
1. Aberrant p16, p53 and Ki-67 immunohistochemistry staining patterns can distinguish solitary keratoacanthoma from cutaneous squamous cell carcinoma.
Carr RA; Mesiano D; Heffron C; Radonic T; Wiggins J; Tso S; Agrawal R; Cheung E; Slater DN; Nichols L; Craig P
Pathology; 2023 Oct; 55(6):772-784. PubMed ID: 37573161
[TBL] [Abstract][Full Text] [Related]
2. Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.
Fan X; Niu X; Wu Z; Yao L; Chen S; Wan W; Huang B; Qi RQ; Zhang T
Biomed Res Int; 2022; 2022():3168503. PubMed ID: 36051475
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing Keratoacanthoma from Well-Differentiated Cutaneous Squamous Cell Carcinoma Using Single-Cell Spatial Pathology.
Veenstra J; Ozog D; Loveless I; Adrianto I; Dimitrion P; Subedi K; Friedman BJ; Zhou L; Mi QS
J Invest Dermatol; 2023 Dec; 143(12):2397-2407.e8. PubMed ID: 37419445
[TBL] [Abstract][Full Text] [Related]
4. Keratoacanthoma versus squamous cell carcinoma. An immunohistochemical reappraisal of p53 protein and proliferating cell nuclear antigen expression in keratoacanthoma-like tumors.
Cain CT; Niemann TH; Argenyi ZB
Am J Dermatopathol; 1995 Aug; 17(4):324-31. PubMed ID: 8600793
[TBL] [Abstract][Full Text] [Related]
5. The role of p53, Ki-67 and laminin expression in the differential diagnosis of keratoacanthoma and well-differentiated SCC.
Turan G; Altun E; Aslan F; Kulahci O
Indian J Pathol Microbiol; 2019; 62(4):561-565. PubMed ID: 31611440
[TBL] [Abstract][Full Text] [Related]
6. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Gambichler T; Gnielka M; Rüddel I; Stockfleth E; Stücker M; Schmitz L
Cancer Immunol Immunother; 2017 Sep; 66(9):1199-1204. PubMed ID: 28501937
[TBL] [Abstract][Full Text] [Related]
7. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.
Kaabipour E; Haupt HM; Stern JB; Kanetsky PA; Podolski VF; Martin AM
Arch Pathol Lab Med; 2006 Jan; 130(1):69-73. PubMed ID: 16390241
[TBL] [Abstract][Full Text] [Related]
8. Solitary keratoacanthoma: a self-healing proliferation that frequently becomes malignant.
Sánchez Yus E; Simón P; Requena L; Ambrojo P; de Eusebio E
Am J Dermatopathol; 2000 Aug; 22(4):305-10. PubMed ID: 10949454
[TBL] [Abstract][Full Text] [Related]
9. The Bcl-xL inhibitor of apoptosis is preferentially expressed in cutaneous squamous cell carcinoma compared with that in keratoacanthoma.
Vasiljević N; Andersson K; Bjelkenkrantz K; Kjellström C; Månsson H; Nilsson E; Landberg G; Dillner J; Forslund O
Int J Cancer; 2009 May; 124(10):2361-6. PubMed ID: 19165861
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of p53 immunohistochemistry in atypical squamous lesions, using a vulvar scoring system.
Niu N; Roy SF; Ko CJ
J Cutan Pathol; 2024 May; 51(5):379-386. PubMed ID: 38317537
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma.
Batinac T; Zamolo G; Coklo M; Hadzisejdic I; Stemberger C; Zauhar G
Pathol Res Pract; 2006; 202(8):599-607. PubMed ID: 16781827
[TBL] [Abstract][Full Text] [Related]
12. p53 protein expression and cell proliferation in non-neoplastic and neoplastic proliferative skin diseases.
Batinac T; Zamolo G; Jonjić N; Gruber F; Petrovecki M
Tumori; 2004; 90(1):120-7. PubMed ID: 15143984
[TBL] [Abstract][Full Text] [Related]
13. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma.
Kerschmann RL; McCalmont TH; LeBoit PE
Arch Dermatol; 1994 Feb; 130(2):181-6. PubMed ID: 8304756
[TBL] [Abstract][Full Text] [Related]
14. P53, p16 and Ki67 immunoexpression in cutaneous squamous cell carcinoma and its precursor lesions.
Marinescu A; Stepan AE; Mărgăritescu C; Marinescu AM; Zăvoi RE; Simionescu CE; Niculescu M
Rom J Morphol Embryol; 2016; 57(2 Suppl):691-696. PubMed ID: 27833960
[TBL] [Abstract][Full Text] [Related]
15. Debulking followed by intralesional 5-fluorouracil for the treatment of cutaneous squamous cell carcinoma and keratoacanthoma: A retrospective analysis.
Hamad J; Jolly PS
Dermatol Ther; 2021 Nov; 34(6):e15139. PubMed ID: 34549487
[TBL] [Abstract][Full Text] [Related]
16. A clinical and biological review of keratoacanthoma.
Tisack A; Fotouhi A; Fidai C; Friedman BJ; Ozog D; Veenstra J
Br J Dermatol; 2021 Sep; 185(3):487-498. PubMed ID: 33864244
[TBL] [Abstract][Full Text] [Related]
17. The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study.
Bedir R; Güçer H; Şehitoğlu İ; Yurdakul C; Bağcı P; Üstüner P
Balkan Med J; 2016 Mar; 33(2):121-7. PubMed ID: 27403379
[TBL] [Abstract][Full Text] [Related]
18. The nuclear factor kappa B p50 subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma.
Fujii M; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
Clin Exp Dermatol; 2011 Oct; 36(7):788-92. PubMed ID: 21883393
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma arising in association with verruca vulgares and HPV-2: a clinicopathologic study with p16 and p53 immunohistochemical studies and human papillomavirus in situ hybridization studies.
Ruhoy SM; Guinee DG; Nuovo G
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):253-61. PubMed ID: 24717230
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma.
Scola N; Segert HM; Stücker M; Altmeyer P; Gambichler T; Kreuter A
Clin Exp Dermatol; 2014 Mar; 39(2):216-8. PubMed ID: 24524559
[No Abstract] [Full Text] [Related]
[Next] [New Search]
